- © 2023 EXO Biomedical, Inc. All rights reserved. ExoSurge® and all logos are trademarks by EXO Biomedical, Inc. Contact Me 0
| Autoimmune Disease |
Our Opportunity
As the third most common cause of chronic illness in the U.S., autoimmune diseases affect as many as 23.5 million people1. More than 80 known autoimmune diseases exist with suboptimal treatment and no cures, representing a leading cause of death and disability.
Current therapeutic modalities include injectable monoclonal antibodies and small molecule oral medicines that do not always achieve optimal and long-lasting disease control. Autoimmune diseases may also require extreme, broadly immunosuppressive approaches (for example, corticosteroids or calcineurin inhibitors) which can leave patients with dampened immune responses, rendering them susceptible to infections and malignancies.
Kyverna aims to successfully apply cell therapy to autoimmunity. We believe that Kyverna’s engineered cells have the potential to address the underlying mechanisms of autoimmune disease with the additional benefits of improving safety and tolerability by minimizing toxicity associated with current treatments.
Potential Disease Targets
In its simplest form, autoimmune disease emerges when the complex network of the normally protective human immune system is unable to discern between self and non-self. Abnormal immunity against self-antigens may be evidenced by a rise in antibodies (called “autoantibodies”) against a variety of molecules. A cell population responsible for the production of antibodies, the B cells, has been identified as playing a key role in so-called humoral auto-immunity.
Our goal is to demonstrate the clinical potential of Kyverna’s engineered T cell therapies as safe, effective, and potentially curative treatments for autoimmune diseases. Our initial disease targets are diseases for which there are no approved treatments, or for which the results of existing treatments could be significantly improved.
LUPUS NEPHRITIS
SYSTEMIC SCLEROSIS
